Eligo Bioscience
Founded Year
2014Stage
Series B | AliveTotal Raised
$53.71MLast Raised
$29.69M | 19 hrs agoAbout Eligo Bioscience
Eligo Bioscience provides biotechnology services. It focuses on the development of biotherapeutics for microbiome precision editing. The company's service involves the use of in vivo gene editing technologies to target the microbiome and address diseases with high unmet needs. It was founded in 2014 and is based in Paris, France.
Loading...
Loading...
Expert Collections containing Eligo Bioscience
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Eligo Bioscience is included in 2 Expert Collections, including Synthetic Biology.
Synthetic Biology
238 items
Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.
Digital Health
10,585 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Eligo Bioscience Patents
Eligo Bioscience has filed 44 patents.
The 3 most popular patent topics include:
- molecular biology
- genetics
- biotechnology
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
11/4/2021 | 11/21/2023 | Molecular biology, Genetics, Biotechnology, Molecular genetics, Genetic engineering | Grant |
Application Date | 11/4/2021 |
|---|---|
Grant Date | 11/21/2023 |
Title | |
Related Topics | Molecular biology, Genetics, Biotechnology, Molecular genetics, Genetic engineering |
Status | Grant |
Latest Eligo Bioscience News
Dec 5, 2023
European Biotechnology Latest News © 18percentgrey - stock.adobe.com 05.12.2023 Eligo Bioscience secures $30m in series B funding, advancing its innovative gene-editing solutions targeting diseases linked to bacterial genes within the human microbiome. Eligo Bioscience SA has secured $30m in a series B funding round led by Sanofi Ventures. The funding includes support from new investor Bpifrance, a French public sector investment bank, and existing backers Khosla Ventures, American venture capital firm, and Seventure Partners, French venture capital firm, signifying the stride toward the company's evolution into a clinical-stage biotech entity. “This is a defining time for Eligo as this funding puts us in a strong position to make a significant leap in treating diseases by editing the genetic makeup of the human microbiome,” said Xavier Duportet, PhD, Chief Executive Officer of Eligo Bioscience. The funding will expedite the development of EB005, Eligo's program targeting moderate to severe acne vulgaris. It aims to generate early human data in a PhIb/IIa clinical trial and facilitate Eligo's expansion into various chronic diseases, including oncology. Eligo Bioscience's method of delivering genetic material to the microbiome in vivo goes beyond typical gene therapy, offering accurate modification of genetic elements within the human microbiome. This unique approach holds potential to alter the course of numerous chronic and life-threatening diseases associated with bacterial gene expression. Share
Eligo Bioscience Frequently Asked Questions (FAQ)
When was Eligo Bioscience founded?
Eligo Bioscience was founded in 2014.
Where is Eligo Bioscience's headquarters?
Eligo Bioscience's headquarters is located at 111 Avenue de, Paris.
What is Eligo Bioscience's latest funding round?
Eligo Bioscience's latest funding round is Series B.
How much did Eligo Bioscience raise?
Eligo Bioscience raised a total of $53.71M.
Who are the investors of Eligo Bioscience?
Investors of Eligo Bioscience include Seventure Partners, Khosla Ventures, Bpifrance, Sanofi Ventures, CARB-X and 5 more.
Who are Eligo Bioscience's competitors?
Competitors of Eligo Bioscience include Locus Biosciences and 1 more.
Loading...
Compare Eligo Bioscience to Competitors
Synthego provides a genome engineering platform. The company provides platforms for science at scale, to access machine learning (ML), automation, and gene editing for creating medicines. Its primary customer base is in the healthcare and medical research industries. It was founded in 2012 and is based in Redwood City, California.
Adaptive Phage Therapeutics runs a clinical-stage company focusing on the development of therapies to combat multi-drug-resistant bacterial infections. The company's main offering includes an ever-expanding collection of bacteriophages, which are viruses that infect bacteria, designed to adapt to and overcome emerging bacterial resistance. It was founded in 2016 and is based in Gaithersburg, Maryland.
Microbiotix is a company focused on the development of treatments for global intractable diseases such as multi-drug resistant bacterial infections, autoimmune diseases, and cancer, operating in the biotechnology and pharmaceutical industry. The company's main offerings include the development of bacteriophage-based super bacteria treatments and microbiome and phage-based treatments. They also provide a microbiota banking service. It was founded in 2016 and is based in Seoul, South Korea.
Locus Biosciences operates as a precision medicine company. It develops bacteriophage-based products to precisely remove pathogenic bacteria from the human body and to leverage the microbiome to treat diseases across multiple therapeutic areas. It was founded in 2015 and is based in Morrisville, North Carolina.
Amyris (NASDAQ: AMRS) offers integrated renewable products by applying industrial synthetic biology to genetically modify microorganisms to serve as living factories. It designs microorganisms to produce defined molecules for use as renewable chemicals and transportation fuels. The company was founded in 2003 and is based in Emeryville, California. In August 2023, Amyris filed for bankruptcy.
Codon Devices is engaged in the field of synthetic biology.
Loading...